The Indian Council of Medical Research (ICMR) and New Delhi-based biotech company Panacea Biotec have announced the initiation of the first-ever Phase 3 clinical trial for a dengue vaccine in India. This landmark trial will evaluate the efficacy of India’s indigenous tet...
Guy B, Saville M, Lang J (2010) Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 6(9):696–705 ArticleCASGoogle Scholar Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J (2011) From research to phase III: preclinical, industrial and clinical development o...
VACCINE effectivenessGENETIC mutationSEROTYPESMore than a hundred thousand dengue cases are diagnosed in India annually, and about half of the country's population carries dengue virus-specific antibodies. Dengue propagates and adapts to the selection pressures imposed by a multitude of fact...
He also said, "After Covishield's success, first time in the world we will be launching malaria vaccine which is desperately needed in the African countries and also in the endemic disease areas of India where hundreds of millions of people are getting affected with malaria."...
dna vaccine for dengue developed india’s first and only dna vaccine candidate for dengue has shown promising results in its preliminary trials. this vaccine is being developed by the national centre for biological sciences, bangalore. know more here . this article is a part of the science & ...
dengue vaccineprospect IndiastatusInfection with dengue virus (DENV) is the most rapidly spreading mosquito-borne viral disease in the world. The clinical spectrum of dengue, caused by any of the four serotypes of DENV, ranges from mild self-limiting dengue fever to severe dengue, in the form...
We anticipate that they will provide a starting point for a wider discussion about the global impact of this disease and will help to guide improvements in disease control strategies using vaccine, drug and vector control methods, and in their economic evaluation. This is a preview of ...
102 The most advanced vaccine candidate, now in phase III clinical studies, is based on four recombinant yellow fever vaccine (YF-17D) virus genomes that carry the genes encoding the surface proteins of the four serotypes of dengue fever virus (in place of the native YFV genes). An up-...
This vaccine underwent placebo-controlled clinical studies in 35,000 children, aged 2–16 years in ten dengue-endemic countries to assess its effectiveness and safety. However, the efficacy of the vaccine was not conclusive [8]. Dengvaxia is one such promising vaccine; however, with low efficacy...
In the absence of a vaccine, vector control is the main strategy to prevent dengue outbreaks. The country paradigm for dengue control is largely passive surveillance and early case detection coupled with rapid mobilization in the case of an outbreak. The first outbreak of DHF occurred in Calcutta...